Literature DB >> 25832910

Autologous serum and plasma rich in growth factors in ophthalmology: preclinical and clinical studies.

Eduardo Anitua1, Francisco Muruzabal1, Ali Tayebba2, Ana Riestra3, Victor L Perez2, Jesus Merayo-Lloves3, Gorka Orive1.   

Abstract

The use of blood derivatives represents an alternative therapeutic approach that is gaining interest in regenerative medicine due to its potential to stimulate and accelerate tissue healing. Autologous serum eye drops and platelet-enriched plasma eye drops are being used in the treatment of different ophthalmological disorders. In this review, we summarize the different blood-derived formulations used in the treatment and care of ocular surface disorders. The biological basis and use of autologous serum and plasma rich in growth factors are deeply evaluated as well as the challenges to be addressed in the future in this new generation of blood-derived therapies.
© 2015 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  autologous serum; cornea; dry eye; eye; ocular surface; plasma rich in growth factors; platelet-rich plasma

Mesh：

Substances：

Year:  2015        PMID： 25832910     DOI： 10.1111/aos.12710

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN： 1755-375X            Impact factor:   3.761


  41 in total

1.  Serum eye drops for the treatment of ocular surface diseases: a systematic review and meta-analysis.

Authors:  Massimo Franchini; Mario Cruciani; Carlo Mengoli; Giuseppe Marano; Enrico Capuzzo; Ilaria Pati; Francesca Masiello; Eva Veropalumbo; Simonetta Pupella; Stefania Vaglio; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2019-05       Impact factor: 3.443

2.  Visual Loss after Platelet-rich Plasma Injection into the Face.

Authors:  Emely Z Karam; Alexander Gan; Rafael Muci Mendoza; Edwing Martinez; Evlyn Perez
Journal:  Neuroophthalmology       Date:  2020-03-26

3.  Allogeneic blood-based therapies: hype or hope?

Authors:  E Anitua; M de la Fuente; J Merayo-Lloves; F Muruzabal; G Orive
Journal:  Eye (Lond)       Date:  2016-12-02       Impact factor: 3.775

Review 4.  Advances in dry eye disease treatment.

Authors:  Erin C O'Neil; Matthew Henderson; Mina Massaro-Giordano; Vatinee Y Bunya
Journal:  Curr Opin Ophthalmol       Date:  2019-05       Impact factor: 3.761

Review 5.  How I treat refractory chronic graft-versus-host disease.

Authors:  Stefanie Sarantopoulos; Adela R Cardones; Keith M Sullivan
Journal:  Blood       Date:  2019-01-23       Impact factor: 22.113

6.  Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret) eye-drops.

Authors:  Ronald Mauricio Sanchez-Avila; Jesus Merayo-Lloves; Ana Cristina Riestra; Luis Fernandez-Vega Cueto; Eduardo Anitua; Leire Begoña; Francisco Muruzabal; Gorka Orive
Journal:  Int Ophthalmol       Date:  2017-06-15       Impact factor: 2.031

Review 7.  A Review of Management Strategies for Nociceptive and Neuropathic Ocular Surface Pain.

Authors:  Harrison Dermer; Daniella Lent-Schochet; Despoina Theotoka; Christian Paba; Abdullah A Cheema; Ryan S Kim; Anat Galor
Journal:  Drugs       Date:  2020-04       Impact factor: 9.546

8.  A novel personalized 3D injectable protein scaffold for regenerative medicine.

Authors:  Eduardo Anitua; Ander Pino; María Troya; Pedro Jaén; Gorka Orive
Journal:  J Mater Sci Mater Med       Date:  2017-12-14       Impact factor: 3.896

9.  Use of autologous plasma rich in growth factors fibrin membrane in the surgical management of ocular surface diseases.

Authors:  Alfonso L Sabater; Hazem M Mousa; Xavier Quinones; Felipe Valenzuela; Ronald Mauricio Sanchez Avila; Gorka Orive; Eduardo Anitua; Jesús Merayo; Victor L Perez
Journal:  Int Ophthalmol       Date:  2021-03-21       Impact factor: 2.031

10.  Effects of subtenon-injected autologous platelet-rich plasma on visual functions in eyes with retinitis pigmentosa: preliminary clinical results.

Authors:  Umut Arslan; Emin Özmert; Sibel Demirel; Firdevs Örnek; Figen Şermet
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-03-15       Impact factor: 3.117
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.